Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
23.25 USD -1.19% Intraday chart for 4D Molecular Therapeutics, Inc. -7.92% +14.76%
04-15 Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target MT
04-15 RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier MT

Business Summary

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Number of employees: 147

Sales per Business

USD in Million2022Weight2023Weight Delta
Gene Therapeutic Products
100.0 %
3 100.0 % 21 100.0 % +562.29%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
97.3 %
0 1.1 % 20 97.3 % +57,488.57%
Netherlands
2.7 %
3 98.9 % 1 2.7 % -81.67%

Managers

Managers TitleAgeSince
Theresa Janke FOU
 Founder 49 11/09/13
David Kirn FOU
 Founder 62 11/09/13
Uneek Mehra DFI
 Director of Finance/CFO - 11/09/23
Fariborz Kamal PSD
 President 61 30/09/18
Robert Kim CTO
 Chief Tech/Sci/R&D Officer 63 30/09/22
Noriyuki Kasahara CTO
 Chief Tech/Sci/R&D Officer 62 22/09/22
Julian Pei IRC
 Investor Relations Contact - -
Scott Bizily HRO
 Human Resources Officer 52 31/08/21
An Song PRN
 Corporate Officer/Principal - 31/08/21

Members of the board

Members of the board TitleAgeSince
John Milligan CHM
 Chairman 63 31/07/20
Susannah Gray BRD
 Director/Board Member 63 30/06/20
Charles Theuer BRD
 Director/Board Member 60 31/12/15
David Kirn FOU
 Founder 62 11/09/13
Jacob Chacko BRD
 Director/Board Member 45 28/02/19
Shawn Tomasello BRD
 Director/Board Member 65 17/11/20
Nancy Miller-Rich BRD
 Director/Board Member 65 17/11/20
Noriyuki Kasahara CTO
 Chief Tech/Sci/R&D Officer 62 22/09/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 51,157,472 49,349,028 ( 96.46 %) 0 96.46 %

Shareholders

NameEquities%Valuation
Viking Global Investors LP
9.619 %
4,787,914 9.619 % 153 M $
Viking Global Investors LP
8.534 %
4,247,914 8.534 % 135 M $
RA Capital Management LP
8.364 %
4,163,211 8.364 % 133 M $
BVF, Inc.
8.051 %
4,007,413 8.051 % 128 M $
Venrock Associates
6.879 %
3,424,031 6.879 % 109 M $
BlackRock Advisors LLC
6.560 %
3,265,248 6.560 % 104 M $
Janus Henderson Investors US LLC
6.214 %
3,093,296 6.214 % 99 M $
Deep Track Capital LP
4.589 %
2,284,372 4.589 % 73 M $
Vanguard Fiduciary Trust Co.
3.750 %
1,866,849 3.750 % 59 M $
Morgan Stanley Investment Management, Inc.
3.152 %
1,568,784 3.152 % 50 M $

Company contact information

4D Molecular Therapeutics, Inc.

5858 Horton Street Suite 455

94608, Emeryville

+

http://www.4dmoleculartherapeutics.com
address 4D Molecular Therapeutics, Inc.(FDMT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for 4D Molecular Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.25 USD
Average target price
54.22 USD
Spread / Average Target
+133.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
4D MOLECULAR THERAPEUTICS, INC. Stock 4D Molecular Therapeutics, Inc.
+14.76% 1.19B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. Company 4D Molecular Therapeutics, Inc.